Fourth study published over two-year span that analyzes key leukemia protein
Northwestern Medicine scientists have discovered two successful therapies that slowed the progression of pediatric leukemia in mice, according to three studies published over the last two years in the journal Cell, and the final paper published Dec. 20 in Genes & Development.
When a key protein responsible for leukemia, MLL, is stabilized, it slows the progression of the leukemia, the most recent study found. The next step will be to combine the treatments from the past two years of research into a pediatric leukemia “super drug” to test on humans in a clinical trial.
The survival rate is only 30 percent for children diagnosed with MLL-translocation leukemia, a cancer that affects the blood and bone marrow. Patients with leukemia have a very low percentage of red blood cells, making them anemic, and have approximately 80 times more white blood cells than people without cancer.
30%Current survival rate for pediatric leukemia patients.
“These white blood cells infiltrate many of the tissues and organs of the affected individuals and is a major cause of death in leukemia patients,” said senior author Ali Shilatifard, the Robert Francis Furchgott Professor of Biochemistry and Molecular Genetics and Pediatrics, the chairman of biochemistry and molecular genetics and the director of Northwestern’s Simpson Querrey Center for Epigenetics. “This is a monster cancer that we’ve been dealing with for many years in children.”
There are several types of leukemia. This research focused on the two most common found in infants through teenagers: acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
For the past 25 years, Shilatifard’s laboratory has been studying the molecular function of MLL within its complex known as COMPASS (Complex Proteins Associated with Set1). Most recently, it was demonstrated that COMPASS components are one of the most frequently identified mutations in cancer.The next step of this work will be to bring the drug to a clinical trial setting, which Shilatifard said he hopes will happen in the next three to five years.
“I’ve been working on this translocation for more than two decades, and we’re finally at the point where in five to 10 years, we can get a drug in kids that can be effective,” Shilatifard said. “If we can bring that survival rate up to 85 percent, that’s a major accomplishment.”
Earlier work from Shilatifard’s laboratory published in Cell in 2018 identified compounds that could slow cancer growth by interrupting a gene transcription process known as “Super Elongation Complex” (SEC). It was the first compound in its class to do this.
This MLL stabilization process discovered in the most recent paper could potentially work in cancers with solid tumors, such as breast or prostate cancer, said first author Zibo Zhao, a postdoctoral research fellow in Shilatifard’s lab.
“This opens up a new therapeutic approach not only for leukemia, which is so important for the many children who are diagnosed with this terrible cancer, but also for other types of cancers that plague the population,” Zhao said.
“The publication of these four papers and the possibility of a future human clinical trial could not have happened if it weren’t for the cross-disciplinary collaboration at Northwestern,” Shilatifard said.
The Latest on: Pediatric leukemia
via Google News
The Latest on: Pediatric leukemia
- “Maddox Strong” T-shirts bring awareness to leukemia at AJC Peachtree Road Raceon July 4, 2019 at 10:16 am
In November, doctors diagnosed Kelly’s then-4-year-old son, Maddox, with leukemia. Commonly affecting children, leukemia is a type of cancer that attacks bone marrow and blood-forming tissues and ... […]
- Temperatures and blood counts in pediatric patients treated with chemotherapy for cancer, NCT01683370on July 3, 2019 at 2:11 am
acute myeloid leukemia in 2, Non-Hodgkin lymphoma in 2, central nervous system tumor in 5, and other solid tumors in 12) were comparable with an unselected population of pediatric patients with cancer ... […]
- EHR Tool Searches Data for Child Leukemia Patients for Studieson July 2, 2019 at 9:48 am
“We found that over half of the children referred to an inpatient or outpatient clinic with a leukemia or lymphoma diagnosis in their charts did not actually have cancer,” said Phillips. ... […]
- Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market to Reach $3.52 Bn, Globally, by 2026 at 5.3% CAGR: Allied Market Researchon July 2, 2019 at 4:59 am
Growing incidences of acute lymphoblastic leukemia, and increase in number ... and Oncaspar), and Type (Pediatric and Adult): Global Opportunity Analysis and Industry Forecast, 2019–2026." ... […]
- A Win for Less-Intense Therapy in Pediatric ALLon July 1, 2019 at 2:28 pm
Intermittent treatment with a widely used drug for pediatric acute lymphoblastic leukemia (ALL) achieved disease control similar to continuous therapy while significantly reducing toxicity, a ... […]
- Couple who both battled leukemia together as kids get married: ‘It was a dream’on June 28, 2019 at 5:07 am
(MORE: 8-year-old girl battling leukemia designs her own Lilly Pulitzer print to benefit children's cancer research) "Whenever we struggle with something, we say, 'My chemo brain has the best of me ... […]
- Couple who fought leukemia together since they were kids gets marriedon June 28, 2019 at 12:55 am
Even after they became leukemia-free, the two remained easy ... “From when we started dating, it was surreal that he went from being a childhood best friend to my boyfriend,” Settle said. ... […]
- Childhood Leukemia Cannot Hide from the Immune System: Studyon June 27, 2019 at 7:40 pm
St. Jude Children's Research Hospital scientists have discovered that having few mutations, pediatric acute lymphoblastic leukemia does not escape immune detection. The findings, which appear today in ... […]
- Tool dearches EHR data to find child leukemia patients for clinical studieson June 26, 2019 at 11:10 pm
"We found that over half of the children referred to an inpatient or outpatient clinic with a leukemia or lymphoma diagnosis in their charts did not actually have cancer," said Phillips. ... […]
- Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 + T cell responseson June 26, 2019 at 8:53 pm
1 Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA. 2 Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, TN 38163, ... […]
via Bing News